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A B S T R A C T
Aim: This article aimed to assess the efﬁcacy of Schwann cell transplantation on motor function recovery
in animal model of spinal cord injuries via meta-analysis.
Methods: An extended search was carried out in the electronic databases of Medline (via PubMed),
EMBASE (via OvidSP), CENTRAL, SCOPUS, Web of Science (BIOSIS), and ProQuest. Finally, 41 eligible
studies conducted on 1046 animals including 517 control animals and 529 transplanted animals were
included in the meta-analysis. Pooled standardized mean difference (SMD) and odds ratio (OR) with 95%
conﬁdence interval (95% CI) were reported.
Results: The ﬁndings showed that treatment with Schwann cells leads to a modest motor function
recovery after spinal cord injury (SMD = 0.85; 95% CI: 0.63–1.07; p < 0.001). Transplantation of these cells
in acute phase of the injury (immediately after the injury) (OR = 4.30; 95% CI: 1.53–12.05; p = 0.007),
application of mesenchymal/skin-derived precursors (OR = 2.34; 95% CI: 1.28–4.29; p = 0.008), and cells
with human sources are associated with an increase in efﬁcacy of Schwann cells (OR = 10.96; 95% CI:
1.49–80.77; p = 0.02). Finally, it seems that the efﬁcacy of Schwann cells in mice is signiﬁcantly lower than
rats (OR = 0.03; 95% CI: 0.003–0.41; p = 0.009).
Conclusion: Transplantation of Schwann cells can moderately improve motor function recovery. It seems
that inter-species differences might exist regarding the efﬁcacy of this cells. Therefore, this should be
taken into account when using Schwann cells in clinical trials regarding spinal cord injuries.
ã 2016 Elsevier B.V. All rights reserved.
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In recent years, cell therapy has been considered as a promising
method in treatment of spinal cord injuries (Hosseini et al., 2015).
Although multiple sources have been proposed for the trans-
planted cells, Schwann cells have always been regarded as one of
the best candidates for this treatment (Kanno et al., 2014; Pearse
et al., 2004a, 2004b; Takami et al., 2002). Schwann cells are
responsible for neural protection and myelination in peripheral
nervous system and normally they are not found in central nervous
system. After injury, these cells migrate to the site of the lesion
through the dorsal root and help the recovery to some extent.
Studies suggest that application of Schwann cells can lead to a
better recovery of sensory and motor function after spinal cord
injuries (Kanno et al., 2014; Takami et al., 2002). However, a
considerable number of surveys have yielded contradictory results
(Barakat et al., 2005; Maldonado et al., 2006; Pearse et al., 2004b).
Recently, two meta-analyses, including data from 14 animal
studies, proposed that transplantation of Schwann cells can
signiﬁcantly improve recovery of motor function in rats after
spinal cord injuries (Lu et al., 2015; Yang et al., 2015a). However,
presence of some limitation such as performing inefﬁcient search,
using unrelated keywords, and being subject to publication bias
warrants the need for a redo of this meta-analysis. In this regard
the present study aimed to re-evaluate the efﬁcacy of Schwann
cells in motor function recovery after spinal cord injury through a
meta-analytic systematic review.
2. Methods
2.1. Search strategy
In this study, an extended search was carried out in the
databases of Medline (via PubMed), EMBASE (via OvidSP),
CENTRAL, SCOPUS, Web of Science (BIOSIS), and ProQuest, from
1 June 1946 until the end of September 2015. Search strategy was
designed based on combining keywords related to “Schwann-like”
and “Schwann cells” with terms related to “spinal cord injury”
(Table 1). The keywords were selected based on three methods: a)
from the Mesh and EMTREE terms; b) based on manual search inTable 1
Keywords used for search in databases of MEDLINE and EMBASE.
Database Search terms
Medline
(PubMed)
(Schwann Cells[mh] OR Schwann Cell*[mh] OR Schwannomas[tiab]
(“Spinal cord injuries”[MeSH] OR Spinal cord contusion[tiab] OR Spin
OR Spinal cord Hemisection[tiab] OR Spinal compression[tiab] OR 
Myelopath*[tiab])
EMBASE
(OvidSP)
exp Schwann Cells/OR (Schwann Cell$ OR Schwannomas OR Schwan
cord contusion OR Spinal cord transection OR Injured spinal cord OR
Cord Laceratio$).ti,ab.the titles and abstracts of the related articles; and c) through
consultation with two specialists.
Findings from PubMed Central were also included when the
PubMed database was searched. Moreover, non-indexed reports
were also searched in Google search engine and Google scholar.
The authors of the related articles were also asked to provide any
unpublished data, information that is not registered or unpub-
lished dissertations, if possible. The ProQuest database was also
precisely searched for related theses. In cases where data were not
available online, the corresponding author of article was contacted.
A reminder was also sent to the author after one week of no
response. If no answer was received, the co-authors were
contacted through social networks such as ResearchGate and
LinkedIn.
In order to ﬁnd further studies and unpublished data, hand-
search was carried out in the bibliography of relevant studies
which yielded two more articles. Furthermore, hand-searching of
journals was also performed. The articles were imported into
EndNote X7 software and then a list of highly focused journals was
created which included journals that had published the highest
number of articles in the ﬁelds of stem cell therapy, neuroscience
and spine. All the issues of these journals were manually searched
and three more articles were found for inclusion in the meta-
analysis.
2.2. Inclusion criteria
In the present study controlled animal surveys were included,
in which the efﬁcacy of Schwann cells in recovery of motor
function after spinal cord injury was evaluated in rat and mice.
Studies in which the cells were changed or modiﬁed in order to
increase their efﬁcacy were excluded. Genetic modiﬁcation for cell
labeling was not considered as an exclusion criterion. A follow up
of less than 4 weeks was another exclusion criterion since the
minimum duration of time needed for the cell therapy to take
effect is three to four weeks. Surveys lacking control groups (sham,
saline treated, or vehicle treated groups) were also excluded. Since
the authors had aimed to evaluate the net effect of Schwann cells in
recovery of motor function, the studies that had used co-
treatments with these cells were also left out. OR Schwann*[tiab] OR Schwann-Like Cell*[tiab] OR SCs[tiab] OR SCs[tiab]) AND
al cord transection[tiab] OR Injured spinal cord[tiab] OR Spinal Cord Traum*[tiab]
Traumatic Myelopath*[tiab] OR Spinal Cord Laceratio*[tiab] OR Post-Traumatic
n$ OR Schwann-Like Cell$ OR SCs).ti,ab. AND exp Spinal cord injuries/OR (Spinal
 Spinal Cord Traum$ OR Spinal cord Hemisection OR Spinal compression OR Spinal
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The ﬁndings of our searches were combined and the duplicate
articles were removed via EndNote (version X7, Thomson Reuters,
2011). Two authors (M.Y and S.S) independently evaluated the
titles and abstracts of the articles and screened potentially eligible
studies. Subsequently, full-texts of these articles were studied and
the ones that met the inclusion criteria were selected. Data were
recorded in a checklist designed based on the guidelines of PRISMA
statement (Moher et al., 2009). Extracted data included a)
information related to characteristics of the animals, b) method
of spinal cord injury induction, c) cell therapy protocol, d) follow
up duration, e) evaluated outcome, and f) possible biases. Two
reviewers assessed methodology of potentially relevant articles
(93% agreement). In cases of disagreement between the two
reviewers, a third person (A.MJ) evaluated the articles and the
problem was solved through discussion with the two authors.
Quality assessment of the studies was performed via the method
suggested by Antonic et al. (Antonic et al., 2013).
2.4. Data synthesis
The target outcome in the present study was motor function
recovery. Data were recorded as means and standard errors. Since
the results were given as charts in most of these surveys, the
method of data extraction from charts, proposed by Sistrom and
Mergo, (Sistrom and Mergo, 2000) was used. The last evaluation of
motor function recovery was included in the study. In cases where
repetitive results were given, the study with the largest sample
size and the longest follow up duration was included.
2.5. Statistical analysis
Data were summarized into mean and standard deviation
ﬁgures and were entered into STATA 11.0 software. For each
individual comparison, a standardized mean difference (SMD) wasFig. 1. Flowchart of including stcalculated with a conﬁdence interval of 95% (95% CI), based on
Hedges’ g. Then a pooled effect size was presented. Evaluation of
publication bias was done through drawing a funnel plot using the
Egger’s and Begg’s tests (Egger et al., 1997). Heterogeneity between
the studies was assessed via Chi-Squared and I2 tests and a p value
of less than 0.1 along with an I2 greater than 50% were considered
as presence of heterogeneity. Fixed effect model was utilized if the
studies were homogenous, and if not, subgroup analysis was
performed to ﬁnd the source of heterogeneity. Random effect
model was ﬁtted for cases with no apparent source of heteroge-
neity. Subgroup analysis was carried out based on animals’ gender,
recipient species, injury model, location of injury, severity of
injury, stem cells derivation origin, intervention phase (acute, sub-
acute, chronic), graft type (allogeneic, xenogeneic), number of
transplanted cells, donor species, use of co-treatment, antibiotic
and immunosuppressive agents use, and blinding of the observer.
Finally a meta-regression was performed in order to ﬁnd the
factors that inﬂuence the efﬁcacy of Schwann cells in motor
function recovery and odds ratio (OR) with a conﬁdence interval of
95% were present. A p value of less than 0.05 was considered as
statistically signiﬁcant in all analyses.
3. Results
3.1. Characteristics of included studies
Search in electronic databases yielded 3409 non-repetitive
records, from which 132 potentially eligible studies were identiﬁed
and eventually 41 studies were included in the meta-analysis (Ban
et al., 2011; Barakat et al., 2005; Barbour et al., 2013; Bunge, 2008;
Firouzi et al., 2006; Flora et al., 2013; Garcia-Alias et al., 2004;
Ghosh et al., 2012; Hill et al., 2012; Hu et al., 2013; Joghataei et al.,
2010; Kamada et al., 2011, 2005; Kanno et al., 2014; Lavdas et al.,
2010; Li et al., 2012; Madigan et al., 2014; Maldonado et al., 2006;
Marcol et al., 2015; Moradi et al., 2012; Niapour et al., 2012;
Papastefanaki et al., 2007; Pearse et al., 2004a, 2004b, 2007; Pengudies in the meta-analysis.
Table 2
Characteristics of included studies.
Author, Year Gender/Species/
Weight
Model/Location of injury a/Severity Cell source/Donor/Graft/Dose/Type/
Intervention time (day)
Immunosuppressive/
Antibiotic/Blinding
Follow up
(day)
Ban et al. (2011) Female/Rat/250–250 Contusion/T10/Moderate Sciatic nerve/Rat/IS/3  106/Allogeneic/7 Yes/Yes/Yes 77
Barakat et al.
(2005)
Female/Rat/180–200 Contusion/T9/Moderate Sciatic nerve/Rat/IS/2  106/Allogeneic/56 No/Yes/No 56
Barbour et al.
(2013)
Female/Rat/180–200 Contusion/T10/Moderate Sciatic nerve/Rat/IS/5 105/Allogeneic/14 No/Yes/Yes 126
Bunge (2008) Female/Rat/250–300 Compression/T9-T11/Moderate Subcutaneous skin cells/Rat/IS/5 105/
Allogeneic/9
Yes/Yes/Yes 56
Firouzi et al.
(2006)
Female/Rat/100–140 Compression/T10/Moderate Sciatic nerve/Rat/IS/5 104/Allogeneic/7 No/Yes/Yes 70
Flora et al. (2013) Female/Rat/180–200 Contusion/T9/Moderate Sciatic nerve/Rat/IS/2  106/Allogeneic/7 No/Yes/Yes 84
Garcia-Alias et al.
(2004)
Female/Rat/200–250 Photochemical/T8/Moderate Sciatic nerve/Rat/IS/1.8  105/Allogeneic/1 No/No/Yes 90
Ghosh et al. (2012) Female/Rat/180–200 Contusion/T9/Moderate Sciatic nerve/Rat/IS/2  106/Allogeneic/7 No/No/Yes 56
Hill et al. (2012) Female/Rat/190–196 Contusion/T9/Moderate Sciatic nerve/Rat/IS/2  106/Allogeneic/7 No/Yes/Yes 70
Hu et al. (2013) Female/Rat/160–180 Contusion/T10/Moderate Sciatic nerve/Rat/IS/4 105/Allogeneic/9 Yes/No/Yes 42
Joghataei et al.
(2010)
Male/Rat/250–300 Contusion/T8-T9/Moderate Sciatic nerve/Rat/IS/3  105/Allogeneic/7 No/Yes/No 56
Kamada et al.
(2005)
Male/Rat/200–200 Transection/T7-T8/Severe MSC/Rat/IS/2  106/Allogeneic/1 Yes/Yes/No 42
Kamada et al.
(2011)
Male/Rat/200–200 Contusion/T9/Moderate MSC/human/IS/2 106/Xenogeneic/7 Yes/Yes/No 35
Kanno et al. (2014) Female/Rat/160–180 Contusion/T8/Moderate Sciatic nerve/Rat/IS/2  106/Allogeneic/7 No/Yes/Yes 84
Lavdas et al. (2010) Female/Mice/20–25 Compression/T7-T9/Moderate Sciatic nerve/Mice/IS/1 105/Allogeneic/1 No/No/Yes 28
Li et al. (2012) Male/Rat/200–250 Contusion/T10/Moderate Sciatic nerve/Rat/IS/9  104/Allogeneic/7 No/Yes/Yes 36
Madigan et al.
(2014)
Female/Rat/230–250 Transection/T9/Severe Sciatic nerve/Rat/IS/2.38  105/Allogeneic/
1
No/Yes/Yes 28
Maldonado et al.
(2006)
Female/Rat/180–220 Contusion/T10-T11/Moderate Sciatic nerve/Rat/IS/5 105/Allogeneic/5 Yes/No/Yes 60
Marcol et al. (2015) Male/Rat/300–300 Compression/T10/Moderate Sciatic nerve/Rat/IT/9  105/Allogeneic/1 No/No/Yes 84
Moradi et al.
(2012)
Male/Rat/250–280 Contusion/T10/Moderate Sciatic nerve/human/IS/5 105/
Xenogeneic/7
Yes/Yes/Yes 56
Niapour et al.
(2012)
Male/Rat/250–300 Contusion/T9-T10/Moderate MSC/human/IS/5 105/Allogeneic/7 Yes/Yes/Yes 62
Papastefanaki et al.
(2007)
Female/Mice/20–25 Compression/T7-T9/Moderate Sciatic nerve/mice/IS/5 105/Allogeneic/1 No/No/Yes 28
Pearse et al.
(2004a)
Female/Rat/160–180 Contusion/T9/Moderate Sciatic nerve/Rat/IS/2  106/Allogeneic/7 No/Yes/Yes 84
Pearse et al.
(2004b)
Female/Rat/160–180 Contusion/T9/Moderate Sciatic nerve/Rat/IS/2  106/Allogeneic/7 No/Yes/Yes 56
Pearse et al. (2007) Female/Rat/180–200 Contusion/T9/Moderate Sciatic nerve/Rat/IS/2  106/Allogeneic/7 No/Yes/Yes 63
Peng et al. (2015) Female/Rat/200–250 Contusion/T8-T9/Moderate Sciatic nerve/Rat/IV/3  106/Allogeneic/1 No/Yes/Yes 56
Pourheydar et al.
(2012)
Female/Rat/250–300 Contusion/T8/Moderate Sciatic nerve/Rat/IS/3  105/Allogeneic/7 No/Yes/Yes 56
Schaal et al. (2007) Female/Rat/180–200 Contusion/C5/Moderate Sciatic nerve/Rat/IS/2  106/Allogeneic/7 No/Yes/Yes 49
Sharp et al. (2012) Female/Rat/160–180 Contusion/T9/Moderate Sciatic nerve/Rat/IS/2  106/Allogeneic/7 No/Yes/Yes 63
Someya et al.
(2008)
Male/Rat/225–250 Contusion/T8-T9/Moderate Sciatic nerve/Rat/IS/5 105/Allogeneic/7 Yes/Yes/Yes 35
Someya et al.
(2008)
Male/Rat/225–250 Contusion/T8-T9/Moderate MSC/Rat/IS/5 105/Allogeneic/7 Yes/Yes/Yes 35
Sparling et al.
(2015)
Male/Rat/300–500 Dorsolateral funiculus lesioning/
C4-C5/Moderate
Subcutaneous skin cells/Rat/IS/2  106/
Allogeneic/1
Yes/Yes/Yes 70
Takami et al.
(2002)
Female/Rat/160–180 Contusion/T9/Moderate Sciatic nerve/Rat/IS/2  106/Allogeneic/7 No/No/Yes 70
Walker et al.
(2015)
Female/Rat/200–250 Contusion/C5/Moderate Sciatic nerve/Rat/IS/1 106/Allogeneic/7 No/No/Yes 70
Wang and Xu
(2014)
Female/Rat/200–220 Contusion/T9/Moderate Sciatic nerve/Rat/IS/1 106/Allogeneic/7 Yes/No/Yes 70
Yan-Wu et al.
(2011)
Female/Rat/220–250 Transection/T9-T10/Severe MSC/human/IS/1 106/Xenogeneic/3 No/Yes/Yes 81
Zaminy et al.
(2013a)
Male/Rat/250–300 Hemisection/T9-T10/Severe MSC/Rat/IS/1 106/Allogeneic/1 No/Yes/No 56
Zaminy et al.
(2013b)
Male/Rat/250–300 Hemisection/T9-T10/Severe MSC/Rat/IS/1 106/Allogeneic/1 No/Yes/No 56
Zhang et al. (2007) Female/Rat/200–250 Transection/T10/Severe Sciatic nerve/Rat/IS/1 106/Allogeneic/1 No/Yes/Yes 54
Zhang et al.
(2010b)
Male/Rat/140–160 Hemisection/T8/Severe Sciatic nerve/Rat/IS/1.5 105/Allogeneic/7 Yes/No/Yes 63
Zhang et al.
(2010a)
Male and Female/Rat/
140–160
Hemisection/T8/Severe Sciatic nerve/Rat/IS/1.5 105/Allogeneic/7 Yes/No/Yes 63
Zhang et al. (2015) Female/Rat/200–250 Contusion/T8-T9/Moderate Sciatic nerve/Rat/IS/1 105/Allogeneic/1 No/Yes/Yes 54
a T: thoracic level; C: cervical level; IS: intra-spinal; IT: intrathecal; IV: intravenous.
M. Hosseini et al. / Journal of Chemical Neuroanatomy 78 (2016) 102–111 105
106 M. Hosseini et al. / Journal of Chemical Neuroanatomy 78 (2016) 102–111et al., 2015; Pourheydar et al., 2012; Schaal et al., 2007; Sharp et al.,
2012; Someya et al., 2008; Sparling et al., 2015; Takami et al., 2002;
Walker et al., 2015; Wang and Xu, 2014; Yan-Wu et al., 2011;
Zaminy et al., 2013a,b; Zhang et al., 2010a,b, 2015, 2007) (Fig. 1).
Characteristics of these studies are presented in Table 2. It is worth
mentioning that two experiments with separate protocols were
extracted from one study (Someya et al., 2008).
Data gathered from 1046 animals, including 517 control
subjects and 529 animals in the transplanted group were analyzed.
28 (68.29%) studies evaluated female animals, 12 (29.27%) surveys
had included male subjects and 1 (2.44%) study assessed both
sexes. Rats were included in 39 (95.12%) studies and 2 (4.88%)
experiments had been conducted on mice. Spinal cord injuries
were induced by contusion model in 26 (63.41%) studies,
compression model in 5 (12.19%) surveys, transection model in
4 (9.76%), and hemisection model in 4 (9.76%) studies. Severity of
injury was moderate in 33 (80.49) studies and it was severe in the
remaining 8 (19.51%) surveys. The mean duration of time between
induction of injury and cell transplantation was 6.6  8.5 days
(ranged from 1 to 56 days). Transplantation was carried out in
acute phase in 12 (29.27%) studies (immediately after injury), in
sub-acute phase in 27 (65.85%) studies (3–9 days), and in chronic
phase in only 2 (4.88%) surveys (more than two weeks after the
injury). Cells were transplanted through intra-spinal method
(intra-lesion) in all the studies except two. Transplant was
allogeneic in 38 (92.68%) studies and xenogeneic in 3 (7.32%)
surveys. The number of transplanted cells varied from 4 105 to
2.2 107 per one kilogram of the animal’s body weight.
3.2. Meta-analysis
In order to evaluate motor function recovery in the included
studies, Basso, Beattie, and Bresnahan score test was used for rats
and Basso Mouse Scale was utilized for mice. No publication bias
was observed (Coefﬁcient = 0.08; 95% CI: 0.34–0.50 p = 0.71)
(Fig. 2). Calculation of pooled SMD showed that transplantation of
Schwann cells lead to a moderate improvement in motor function
recovery (Pooled SMD = 0.85; 95%CI: 0.63–1.07; p < 0.001;
I2 = 62.4%). The results of this section are presented in Fig. 3.
As can be seen, a moderate heterogeneity was observed
between the articles (I2 = 62.4%; p < 0.001) and so subgroup
analysis was performed. Table 3 presents the ﬁndings of this
analysis. The most important sources of heterogeneity were
recipient species, injury model, location of injury, Schwann cells
derivation origin, intervention phase, graft type, number of
transplanted cells, and donor species. Accordingly, the efﬁcacy0
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Fig. 2. Funnel plot for assessment of publication bias.of Schwann cell transplantation was found to be relatively higher
in compression (SMD = 1.04; 95% CI: 0.58–1.49) and hemisection/
transection (SMD = 1.28; 95% CI: 0.71–1.85) models compared to
the contusion model (SMD = 0.70; 95% CI: 0.45–0.96). Moreover,
application of Schwann cells had better effects in motor function
recovery after thoracic injuries (SMD = 0.88; 95% CI: 0.64–1.12)
compared to injuries of cervical region (SMD = 0.56; 95% CI: 0.10–
1.02). The efﬁcacy of Schwann cell transplantation was also found
to be higher when the cells were derived from mesenchymal/skin-
derived precursors cells (SMD = 1.64; 95% CI: 0.94–2.33), when
transplanted in the acute phase (SMD = 1.40; 95% CI: 0.97–1.84),
when the cells are derived from human sources (SMD = 1.52; 95%
CI: 0.55–2.48), and when the observer was not blinded to the
treatment groups (SMD = 1.65; 95% CI: 0.56–2.57).
A meta-regression was performed to evaluate the independent
effect of all these variables, in which all the factors were included in
a regression model along with their effect size (Table 4).
Accordingly, recipient species, donor species, and intervention
phase were found to have inﬂuenced the efﬁcacy of Schwann cell
transplantation in recovery of motor function. The efﬁcacy of these
cells was found to be lower in mice (OR = 0.03; 0.003–0.41;
p = 0.009) compared to rats. Schwann cells were found to improve
motor function recovery to a greater extent, when the cells were
derived from human sources (OR = 10.96; 1.49-80-77; p = 0.02). Cell
therapy in the acute phase (OR = 4.3; 1.53–12.05; p = 0.007) also
showed better results compared to sub-acute (OR = 1.63; 0.63–
4.17; p = 0.29) and chronic phases. A signiﬁcant increase in the
efﬁcacy was also observed when mesenchymal/skin-derived
precursors Schwann cells were used instead of peripheral nerve
derived Schwann cells (OR = 2.34; 95% CI: 1.28–4.29; p = 0.007).
4. Discussion
The present meta-analysis showed that transplantation of
Schwann cells can induce a moderate motor function recovery
after spinal cord injuries. Transplantation of these cells in the acute
phase (immediately after injury) causes the efﬁcacy to be twice the
time when they are transplanted in the sub-acute of chronic phases
(SMD = 1.40 vs. 0.67). Application of mesenchymal/skin-derived
precursors Schwann cells (SMD = 1.64 vs.0.69) and cells with
human sources (SMD = 1.52 vs. 0.79) also nearly doubled the
efﬁcacy of this treatment.
Lu et al. in a similar attempt conducted a meta-analysis in 2015,
including 14 animal studies. They declared that Schwann cell
transplantation can signiﬁcantly improve motor function recovery
in mice after spinal cord injuries, (Lu et al., 2015) while in the
present study, only a moderate improvement was observed. The
study conducted by Lu et al. had some important limitations. It was
written in Chinese language, the authors only found 176 related
non-repetitive articles in their systematic search and they included
unrelated keywords for their search which is indicative of a weak
search strategy that led to inclusion of only 14 studies in their
meta-analysis. This increases the chance of publication bias in their
survey. However, in the present study keywords were selected as
extended as possible and more databases were searched. A great
effort was paid to access gray literatures. This strategy led to
screening of 6391 non-repetitive studies. Even after exclusion of
surveys that had used co-treatments, 41 studies were included in
the meta-analysis. Exclusion of these studies signiﬁcantly de-
creased heterogeneity between the included articles (I2 = 62.4%)
compared to that of Lu’s survey (I2 = 82.2%). Moreover, no
publication bias was observed in the present study. Application
of an extended and more precise search strategy led to inclusion of
more negative studies in our meta-analysis and so the efﬁcacy of
Schwann cells was found to be lower than that of reported by Lu
et al. (Lu et al., 2015).
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Fig. 3. Efﬁcacy of Schwann cell transplantation on motor function recovery.
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study showed that Schwann cells have signiﬁcant beneﬁcial effects
in motor recovery in various animal models of spinal cord injury
(Yang et al., 2015b). However, there are major differences between
the present study and Yang et al. study. The most important
difference is in the search strategy of the studies. Searching in only
one database in addition to Cochrane library, without searching in
gray literature or doing hand search in Yang et al. study resulted in
missing a large number of the articles and only 14 articles were
evaluated in their meta-analysis. While, using an extensive
strategy in the present study led to 41 articles entering the study.
This resulted in major differences in the ﬁndings of the studies. For
instance, Yang et al. study showed that Schwan cells are
substantially beneﬁcial regarding motor recovery in widely-used
spinal cord injury animal models (SMD = 1.83). In contrast, the
ﬁndings of the present study showed that improvement of motor
function recovery after Schwann cell transplantation is only
moderate (SMD = 0.85). In addition, in Yang et al. study some
degrees of publication bias is seen (P forEgger’sTest = 0.087), while in
the present study, no publication bias is observed (P forEgger’sTest =
0.71). Furthermore, the present study showed that there is no
difference regarding effectiveness of stem cells between injury
models, while Yang et al. study showed that Schwann cells have no
effect on improvement of motor recovery in impact (contusion and
compression) models, but lead to motor recovery of animals in
hemisection model.
The moderate effect of Schwann cell transplantation in motor
function recovery after spinal cord injuries could be attributed to
the speciﬁcations of the injury and innate characteristics of
Schwann cells. Although these cells are not found in the central
nervous system, after spinal injury, due to inclusion of the dorsal
root, Schwann cells migrate to the lesion site and inducemyelination and axonal regeneration through their neuro-protec-
tive effects (Guest et al., 2005; Nagoshi et al., 2011). However,
current evidence shows that during spinal injury, supra-spinal
axons rarely regenerate in the site of lesion or at the site of
Schwann cell transplantation and even the regenerated axons are
not able to establish an effective connection with the spinal tissues
(Chau et al., 2004; Golden et al., 2007; Takami et al., 2002).
Accordingly, transplantation of Schwann cells at the site of spinal
cord injury cannot signiﬁcantly improve recovery of the motor
function and that is why it is suggested by many studies that co-
treatments should be used alongside transplantation to improve
motor function recovery (Feng et al., 2005; Joghataei et al., 2010; Li
et al., 2007; Maldonado et al., 2006; Pourheydar et al., 2012; Xia
et al., 2013; Zeng et al., 2005; Zhang et al., 2010a).
Although the overall analysis of this study was indicative of a
moderate efﬁcacy, but application of Schwann cell transplantation
in the acute phase was associated with doubling of the efﬁcacy.
This might be due to the protective role of Schwann cells in
prevention and improvement of inﬂammatory processes. Although
the environment around the site of lesion might be cytotoxic
during the ﬁrst hours after injury, presence of Schwann cells can
induce release of growth factors which can stimulate the injured
neurons for survival or axonal regeneration (Bixby et al., 1988). On
the other hand, in sub-acute and chronic phases, the majority of
axons are damaged and release of these growth factors cannot
induce their effects. The ﬁndings of this study are congruent with
the results of our previous meta-analysis, in which transplantation
of bone marrow-derived mesenchymal cells was shown to exhibit
higher efﬁcacy in improvement of neuropathic pains after spinal
cord injury when performed in the ﬁrst 4 days after injury
(Hosseini et al., 2015).
Table 3
Subgroup analyses of the effect of Schwann cell transplantation on motor function recovery.
P for biasa Model P (I2)b Effect Sizec
(95% CI)
P
Gender
Male 0.84 REM 0.002 (52.0%) 0.85 (0.63–1.07) <0.001
Female 0.37 REM 0.001 (60.6%) 0.62 (0.41–0.85) <0.001
Overall signiﬁcance test among subgroups <0.001
Recipient species
Rat 0.95 REM <0.001 (64.2%) 0.86 (0.63–1.09) <0.001
Mice 0.99 FEM 0.92 (0.0%) 0.81 (0.12–1.49) 0.02
Overall signiﬁcance test among subgroups <0.001
Injury model
Contusion 0.77 REM < 0.001 (63.8%) 0.70 (0.45–0.96) <0.001
Compression 0.64 FEM 0.67 (0.0%) 1.04 (0.58–1.49) <0.001
Hemisection/Transection 0.35 FEM 0.44 (0.0%) 1.28 (0.71–1.85) <0.001
Other 0.99 FEM 0.73 (0.0%) 0.80 (0.17–1.42) 0.013
Overall signiﬁcance test among subgroups <0.001
Location of injury
Cervical 0.91 FEM 0.89 (0.0%) 0.56 (0.10–1.02) 0.02
Thoracic 0.73 REM <0.001 (64.9%) 0.88 (0.64–1.12) <0.001
Overall signiﬁcance test among subgroups <0.001
Severity of injury
Moderate 0.79 REM <0.001 (57.6%) 0.75 (0.53–0.97) <0.001
Severe 0.43 REM <0.001 (69.6%) 1.44 (0.70–2.18) <0.001
Overall signiﬁcance test among subgroups <0.001
Schwann cells derivation origin
Sciatic nerve 0.65 REM 0.001 (50.4%) 0.69 (0.48–0.90) <0.001
Mesenchymal/skin derived cell 0.32 FEM <0.001 (74.1%) 1.64 (0.94–2.33) <0.001
Overall signiﬁcance test among subgroups <0.001
Intervention phased
Acute 0.55 REM 0.006 (57.9%) 1.40 (0.97–1.84) <0.001
Subacute 0.75 REM 0.001 (50.4%) 0.67 (0.44–0.90) <0.001
Chronic 0.99 FEM 0.46 (0.0%) 0.10 (0.48–0.68) 0.74
Overall signiﬁcance test among subgroups <0.001
Graft type
Allogeneic 0.79 REM <0.001 (64.2%) 0.85 (0.61–1.09) <0.001
Xenogeneic 0.29 FEM 0.46 (0.0%) 1.02 (0.47–1.56) <0.001
Overall signiﬁcance test among subgroups <0.001
Number of transplanted cells
< 3 106 cell dose/kg 0.16 FEM 0.19 (22.7%) 0.72 (0.49–0.95) <0.001
3  106 cell dose/kg 0.39 REM <0.001 (72.8%) 0.92 (0.61–1.24) <0.001
Overall signiﬁcance test among subgroups <0.001
Donor species
Rat 0.94 REM <0.001 (63.0%) 0.79 (0.56–1.03) <0.001
Mice 0.99 REM 0.02 (68.5%) 0.81 (0.12–1.49) <0.001
Human 0.41 FEM 0.92 (0.0%) 1.52 (0.55–2.48) <0.001
Overall signiﬁcance test among subgroups 0.95
Use of antibiotic
No 0.11 REM 0.06 (43.2%) 0.78 (0.39–1.16) <0.001
Yes 0.85 REM <0.001 (67.5%) 0.89 (0.62–1.16) <0.001
Overall signiﬁcance test among subgroups <0.001
Use of immunosuppressive agents
No 0.97 REM <0.001 (50.3%) 0.83 (0.56–1.10) <0.001
Yes 0.62 REM 0.02 (66.7%) 0.90 (0.53–1.28) <0.001
Overall signiﬁcance test among subgroups <0.001
Blinding of observer
No 0.26 REM <0.001 (83.1%) 1.65 (0.56–2.75) 0.003
Yes 0.78 REM <0.001 (52.3%) 0.75 (0.55–0.96) <0.001
Overall signiﬁcance test among subgroups <0.001
a Publication bias based on Begg’s and Egger’s test.
b Heterogeneity among studies.
c Standardized mean difference.
d Acute (immediately after injury), subacut: 3–10 days after injury; chronic: equal or more than 14 days. REM: Random effect model; FEM: Fixed effect, CI: Conﬁdence
interval; NA: Not applicable because of low number of included studies.
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Table 4
Meta regression analyses of the effect of Schwann cell transplantation on motor
function recovery.
Variable Odds ratio 95% Conﬁdence Interval P
Gender
Female Ref Ref - - -
Male 1.55 0.89–2.70 0.11
Recipient species
Rat Ref Ref - - -
Mice 0.03 0.003–0.41 0.009
Injury model
Contusion Ref Ref - - -
Compression 1.07 0.45–2.56 0.86
Hemisection/Transection 0.37 0.11–1.25 0.11
Other 0.92 0.12–3.34 0.22
Severity of Injury
Moderate Ref Ref - - -
Severe 2.07 0.66–6.58 0.21
Location of injury
Thoracic Ref Ref - - -
Cervical 0.84 0.39–1.81 0.65
Stem cells derivation origin
Sciatic Ref Ref - - -
Mesenchymal/skin derived cell 2.34 1.28–4.29 0.008
Donor species
Rat Ref Ref - - -
Human 10.96 1.49–80.77 0.02
Intervention phase a
Chronic Ref Ref - - -
Subacute 1.63 0.63–4.17 0.29
Acute 4.30 1.53–12.05 0.007
Graft type
Allogeneic Ref Ref - - -
Xenogeneic 0.54 0.01–1.09 0.06
Number of transplanted cells
< 3  106 cell dose/kg Ref Ref - - -
3 106 cell dose/kg 1.20 0.68–2.1 0.52
Use of immunosuppressive agents
No Ref Ref - - -
Yes 0.78 0.46–1.33 0.34
Use of antibiotic
No Ref Ref - - -
Yes 0.77 0.46–1.32 0.33
Blinding of observer
No Ref Ref - - -
Yes 0.79 0.36–1.76 0.56
a Acute (immediately after injury), subacut: 3–10 days after injury; chronic: equal
or more than 14 days. Ref: Reference category.
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Schwann cells is using peripheral nerves; however, recently some
studies have used other sources including mesenchymal/skin-
derived precursor Schwann cells. In these surveys, after differenti-
ation to Schwann cells, they are transplanted at the site of spinal
cord injury (Bunge, 2008; Kamada et al., 2011, 2005; Niapour et al.,
2012; Someya et al., 2008; Yan-Wu et al., 2011; Zaminy et al., 2013a,
2013b). Subgroup analysis in the present study showed that in
comparison with earlier derivation methods (from peripheral
neurons), transplantation of mesenchymal/skin derived Schwann
cells is associated with an increase in the recovery of motor
function. This could be attributed to the modulation of inﬂamma-
tory/immune responses by mesenchymal cells, since transplanted
Schwann cells might be at different levels of differentiation andsome might have preserved characteristics of mesenchymal cells
(Urdzíková et al., 2014; Watanabe et al., 2015). Moreover, skin-
derived Schwann cells are better at migration to the injured site
and establishment of effective synaptic connections compared to
peripheral nerves. These cells can modify the adjacent host tissue
which can decrease gliosis (Biernaskie et al., 2007).
Application of human Schwann cells was another factor that
increased efﬁcacy of this treatment in motor function recovery. In
four studies included in the meta-analysis, Schwann cells had
human sources (Kamada et al., 2011; Moradi et al., 2012; Niapour
et al., 2012; Yan-Wu et al., 2011), in three of which the Schwann
cells were derived from mesenchymal stem cells (Kamada et al.,
2011; Niapour et al., 2012; Yan-Wu et al., 2011). Therefore, the
greater efﬁcacy of human-derived cells might be caused by the
anti-inﬂammatory and protective effects of mesenchymal cells
rather than the Schwann cells (Singer and Caplan, 2011).
Mesenchymal cells exhibit immunomodulatory effects (Alunno
et al., 2014; Coulson-Thomas et al., 2014; Hou et al., 2014;
Menendez et al., 2014; Montespan et al., 2014; Nauta and Fibbe,
2007; Wang et al., 2009) and when transplanted at a suitable time,
they can minimize the inﬂammatory processes and damages
caused by the immune system (Oudega and Ritfeld, 2014).
Transplantation of these cells can decrease proliferation of glial
cells and improve recovery by biologically active molecules
through regulating release of cytokines and growth factors.
Furthermore, their role in vascularization might induce generation
of new vasculature in the spine (Hua et al., 2014; Kuchroo et al.,
2014).
The results of the present study were also indicative of inter-
species differences and efﬁcacy of Schwann cell transplantation
was found to be lower in mice, compared to rats (OR = 0.03).
Although mice were only included in two studies, the differences
cannot be ignored. The Lu et al. (Lu et al., 2015) and Yang et al.
studies did not assess the inter-species differences of Schwann cell
efﬁcacy on motor function recovery after SCI. Therefore, compari-
son is not possible. Nevertheless, similar ﬁndings were also
observed in our previous meta-analysis (Hosseini et al., 2015).
Further investigations are required to conﬁrm or reject the inter-
species differences regarding treatment response to Schwann cell
transplantation. If an inter-species difference exists regarding
effectiveness of Schwann cells, more caution should be taken
regarding using these cells in clinical trials. Therefore, it is
suggested to evaluate the role of inter-species differences in
effectiveness of Schwann cell transplantation in spinal cord injury
recovery before carrying out any clinical trials.
The nature of this meta-analysis can be pointed out as one of the
most important limitations of this survey. Due to their innate
limitation in evaluating all the confounding factors, behavioral
studies cannot deﬁnitely prove causal relationships. Although we
tried our best to include studies with similar methodologies and
controlling methods for confounding factors, but even in ideal
situations these objectives cannot be reached. The presence of
moderate heterogeneity was another limitation of this study which
led the meta-analysis to be designed based on random effect
model. In order to overcome this issue, subgroup analysis was
performed which eliminated heterogeneity in 8 cases (Table 3).
5. Conclusion
Efﬁcacy of Schwann cell transplantation in spinal cord injuries
is evaluated in several studies, the results of which are somewhat
incongruent. In this regard, we aimed to pool all these results in
order to reach a consensus through a meta-analytic approach. The
ﬁndings of this meta-analysis showed that transplantation of
Schwann cells can moderately improve motor function recovery.
110 M. Hosseini et al. / Journal of Chemical Neuroanatomy 78 (2016) 102–111Finally it seems that inter-species differences might exist regarding
the efﬁcacy of this treatment protocol.
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